IDEAYA Biosciences, Inc. (IDYA) has been beaten down lately with too much selling pressure. While the stock has lost 8.6% ...

Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

Oppenheimer lowered the firm’s price target on Ideaya Biosciences (IDYA) to $40 from $53 and keeps an Outperform rating on the shares after the ...

While Ideaya is letting Amgen go, it is retaining an interest in MAT2A-PRMT5 combinations. Ideaya has a PRMT5 inhibitor, ...

In a challenging year for biotech firms, Ideaya Biosciences Inc . (NASDAQ:IDYA) stock has reached a 52-week low, touching down at $21.02. According to InvestingPro data, the company maintains strong ...

Ideaya is financially strong, with $1.2 billion in cash reserves, sufficient to fund operations into at least 2028. Click ...

Reports Q4 revenue $7M, consensus $4.31M. The net loss for the three months ended December 31, 2024, was $130.3M compared to the net loss of ...

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of ...

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced financial results for the quarter and full ...

IDEAYA BIOSCIENCES ($IDYA) posted quarterly earnings results on Thursday, February 13th. The company reported earnings of -$1.49 per share, missing estimates of -$0. ...

IDEAYA Biosciences named Joshua Bleharski as its top finance chief, effective in early May.

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted ...